Mescaline Interactions

A

  • Amitriptyline - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Azacyclonol - pretreatment likely attenuated the effects of mescaline; treatment during the MDMA peak started to block the actions of mescaline; no differences in mescaline effects

B

  • Bupropion - potential increased and prolonged effects of mescaline, with higher blood concentrations for longer; may increase the risk of seizure in combination; consider tapering and discontinuing at least 2 weeks prior or a 25% reduced dose of MDMA

  • Buspirone - loss of psychedelic effect; consider tapering and discontinuing at least 5 days prior

C

  • Chlorpheniramine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Chlorpromazine - reduction in acute anxiety symptoms

  • Citalopram - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Clomipramine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

D

  • Desipramine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Desvenlafaxine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Duloxetine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

E

  • Escitalopram - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

F

  • Fluoxetine - loss of psychedelic effect; consider tapering and discontinuing at least 6 weeks prior

  • Fluvoxamine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

I

  • Imipramine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Isocarboxazid - potential risk of serotonin syndrome or hypertensive crisis; consider tapering and discontinuing at least 2 weeks prior

L

  • Levomilnacipran - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

M

  • Mirtazapine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Moclobemide - potential risk of serotonin syndrome or hypertensive crisis; consider tapering and discontinuing at least 2 weeks prior

N

  • Nortriptyline - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

P

  • Paroxetine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Phenelzine - potential risk of serotonin syndrome or hypertensive crisis; consider tapering and discontinuing at least 2 weeks prior

  • Promazine - reduction in acute anxiety symptoms

S

  • Selegiline - potential intensified effects; potential risk of serotonin syndrome; consider tapering and discontinuing at least 2 weeks prior

  • Sertraline - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

T

  • Tranylcypromine - potential risk of serotonin syndrome or hypertensive crisis; consider tapering and discontinuing at least 2 weeks prior

  • Trazodone - loss of psychedelic effect; consider tapering and discontinuing at least 5 days prior

V

  • Venlafaxine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Vilazodone - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Vortioxetine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

Numbers & Symbols

  • 2C-O - potentiated the effects of mescaline, decreased ability to concentrate

LSD

DMT